Alimera Sciences (NASDAQ:ALIM) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on ALIM. Maxim Group reissued a “hold” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Alliance Global Partners reaffirmed a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, HC Wainwright cut Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price objective on the stock. in a research report on Tuesday, June 25th.

Alimera Sciences Stock Performance

NASDAQ ALIM opened at $5.54 on Wednesday. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The stock has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta of 1.25. The stock’s fifty day moving average price is $5.55 and its 200-day moving average price is $4.63. The company has a current ratio of 2.79, a quick ratio of 2.62 and a debt-to-equity ratio of 1.80.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. The company had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.76 million. As a group, equities analysts forecast that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

Several institutional investors have recently modified their holdings of the business. Fifth Lane Capital LP purchased a new position in Alimera Sciences in the first quarter worth about $83,000. Vanguard Group Inc. boosted its position in Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new position in Alimera Sciences in the first quarter worth about $169,000. Ancora Advisors LLC purchased a new position in Alimera Sciences in the first quarter worth about $915,000. Finally, Deltec Asset Management LLC purchased a new position in Alimera Sciences in the second quarter worth about $690,000. 99.83% of the stock is owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).